Advertisement
U.S. markets close in 4 hours 50 minutes

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
72.40+0.84 (+1.17%)
As of 11:09AM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close71.56
Open72.38
Bid72.48 x 1200
Ask72.56 x 1100
Day's Range71.70 - 72.88
52 Week Range42.01 - 76.11
Volume104,686
Avg. Volume887,678
Market Cap7.009B
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-1.46
Earnings DateMay 02, 2024 - May 06, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est83.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ITCI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intra-Cellular Therapies Inc.
    CYTK: Rating increased to a BUYCYTOKINETICS INC has an Investment Rating of BUY; a target price of $81.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    Intra-Cellular Therapies to Present at the 44th Annual TD Cowen Health Care Conference

    NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 44th Annual TD Cowen Health Care Conference on Tuesday, March 5, 2024 at 11:10 a.m. ET in Boston, MA. The live and archived webcast can be accessed under "Events

  • Simply Wall St.

    Intra-Cellular Therapies Full Year 2023 Earnings: EPS Beats Expectations

    Intra-Cellular Therapies ( NASDAQ:ITCI ) Full Year 2023 Results Key Financial Results Revenue: US$464.4m (up 86% from...

  • Insider Monkey

    Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript

    Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Q4 2023 Earnings Call Transcript February 22, 2024 Intra-Cellular Therapies, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.44. Intra-Cellular Therapies, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and […]